Publicaciones científicas
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Philippe Moreau 1 , Ajai Chari 2 , Albert Oriol 3 , Joaquin Martinez-Lopez 4 , Mathias Haenel 5 , Cyrille Touzeau 6 , Sikander Ailawadhi 7 , Britta Besemer 8 , Javier de la Rubia Comos 9 10 , Cristina Encinas 11 , Maria-Victoria Mateos 12 , Hans Salwender 13 , Paula Rodriguez-Otero 14 , Cyrille Hulin 15 , Lionel Karlin 16 , Anna Sureda Balari 17 , Joan Bargay 18 , Lotfi Benboubker 19 , Laura Rosiñol 20 , Stefano Tarantolo 21 , Howard Terebelo 22 , Shiyi Yang 23 , Jianping Wang 23 , Ivo Nnane 23 , Ming Qi 23 , Michele Kosh 23 , Maria Delioukina 23 , Hartmut Goldschmidt 24
Daratumumab is approved in many countries as monotherapy and in combination regimens for relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma [1,2,3]. Daratumumab-based combinations have also demonstrated encouraging efficacy in lenalidomide-refractory RRMM [4, 5]. Carfilzomib is approved as monotherapy and in combination regimens, including daratumumab and dexamethasone (D-Kd), for RRMM [6]. In the phase 3 CANDOR study, D-Kd (intravenous [IV] daratumumab; carfilzomib 56 mg/m2 twice weekly) improved progression-free survival (PFS) versus Kd in the overall population and lenalidomide-refractory patients [7, 8]. In the phase 3 A.R.R.O.W. study, once-weekly carfilzomib (70 mg/m2) significantly prolonged PFS versus twice-weekly carfilzomib (27 mg/m2), providing a safe and more convenient Kd dosing regimen [9].
CITA DEL ARTÍCULO Blood Cancer J. 2023 Mar 7;13(1):33. doi: 10.1038/s41408-023-00805-x
Nuestros autores
